Ignite Creation Date:
2024-05-06 @ 12:14 PM
Last Modification Date:
2024-10-26 @ 12:56 PM
Study NCT ID:
NCT03711032
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2018-10-15
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Bacillus Calmette-Guerin BCG in High-Risk Non-Muscle Invasive Bladder Cancer HR NMIBC MK-3475-676KEYNOTE-676
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC